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Heart rate responses during treatment of hypertension 
with propranolol 
The clinical usefulness of the nitroglycerin test 
Increments in heart rate during the TNG test (sublingual nitroglycerin with assumption 
of upright posture), passive head-up tilt, and postrecumbency standing were compared to the 
effects of intravenous isoproterenol in 15 mild hypertensives during administration of 
placebo and two dosage levels of propranolol. TNG test results correlated with 
responsiveness to isoproterenol, but nitroglycerin tachycardia was reduced only about 50% 
during propranolol treatment. The TNG response was almost maximally inhibited by 
160 mg /day of propranolol while the response to postrecumbency standing was inhibited 
only by a dose of 320 mg /day. The results indicate that: (1) the TNG test is of 
limited value in the assessment of beta adrenergic blockade in hypertensive patients, 
and (2) propranolol in a dose of 160 mglday induces near-maximal cardiac blockade. 
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The clinical effects of beta adrenergic block-
ing drugs have been investigated extensively 
and there has been an expansion of the uses 
of beta receptor blocking drugs, e.g., in the 
treatment of angina pectoris and hyperten-
sion.7, 9, 10. 18 
Intravenous infusion of the specific beta 
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receptor agonist, isoproterenol, has been used 
to test the degree of blockade during admin-
istration of beta adrenergic blockers.2, 17 Fitz-
gerald 6 suggested that the increase of heart 
rate following sublingual nitroglycerin provides 
a simpler means for clinical estimation of the 
degree of beta receptor blockade. 
In our study, two indirect methods for esti-
mation of the degree of beta adrenergic block-
ade have been compared to the effects of in-
travenous administration of isoproterenol: the 
effect on heart rate of (1) sublingual nitro-
glycerin with assumption of upright postures, 
and (2) 10 min of 45° head-up tilt. These 
maneuvers have been compared during ad-
ministration of placebo and two dosage levels 
of propranolol to 15 male subjects with mild 
essential hypertension. The findings were also 
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Table I. Patient information 
Patient Age Eye 
No. (yr) Race* groundst 
1 50 C I 
2 50 B II 
3 55 B I 
4 53 C I 
5 66 C I 
6 40 C II 
7 27 B 0 
8 52 C I 
9 49 C II 
10 45 C II 
11 44 C I 
12 41 C II 
13 43 C II 
14 35 C II 
15 26 C I 
* C: Caucasian; B: Black. 
tKeith, Wagner, and Barker classification. 
:j:Left ventricular hypertrophy in ECG or chest x-ray. 
Serum 
creatinine 
(mg/lOO ml) LVH+ 
0.9 
1.1 
1.0 
1.0 
1.2 
1.6 
1.1 
0.9 
1.1 + 
1.2 
1.0 
1.1 + 
1.0 
0.9 
1.1 
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Initial 
BP§ 
(mm Hg) 
159/ 98 
150/110 
155/110 
180/120 
169/ 86 
174/137 
134/ 95 
155/108 
200/128 
161/111 
177/107 
184/105 
140/ 96 
162/110 
165/ 90 
§ Measured after 15-min recumbency in the clinic following 4 wk of placebo treatment. 
Table II. Change in heart rate (beats Imin ± SEM) during various stimulating maneuvers 
Propranolol Propranolol 
Placebo (2 wk) (4 wk) 
Stimulus N I Heart rate N I Heart rate N I Heart rate 
Nitroglycerin 14 +37 ± 3.8 13 +21 ± 3.1 * 12 +17±2.5t 
and standing 
Isoproterenol 15 +41 ± 3.5 14 +5±1.1t 
(3.0 ILg/min x 3 min) 
Tilt 14 + 8 ± 2.2 11 + 3 ± 1.0 
(45 0 x 10 min) 
Standing 13 + 9 ± 2.8 15 + 6 ± 1.3 15 + 4 ± 1.8 
(2 min) 
Heart rate responses in all patients during the different treatment periods. 
Statistical comparisons within the group, compared to the placebo value (paired t test). 
*p < 0.01; tp < 0.001. 
compared with increases in heart rate induced 
by standing during clinic visits and with plasma 
propranolol concentrations. 
Methods 
Material. The subjects were 15 male patients 
with mild to moderate essential hypertension 
(Table I), average age 44 yr (range, 26 to 66). 
Before entering the study all patients but two 
were receiving antihypertensive therapy, usu-
ally alpha methyldopa with or without diuretics. 
Secondary causes of hypertension were ex-
cluded by thorough clinical examination, rapid-
sequence intravenous urography, and labora-
tory studies (serum electrolytes, creatinine 
clearance, plasma renin activity, and urinary 
excretion of aldosterone, epinephrine, and 
norepinephrine) . 
Heart rate response tests. 
Nitroglycerin and standing. Pulse rate was 
measured at the wrist by one of the investiga-
tors (L. H.) after at least 15 min of recumbent 
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Fig. 1. Correlations between increase of heart rate 
in response to sublingual nitroglycerin and isopro-
terenol infusions during placebo therapy . ~, Isopro-
terenol , 1.0 fJ.g /min (r = 0.35\ , P > 0.05). 0, 2.0 
fJ.g/min (r = 0.510, P < 0.05) . • , 3 .0 fJ.g/min 
(r = 0 .633 , P < 0.005) . 
rest in a quiet, comfortable room. A tablet 
containing 0.4 mg of nitroglycerin was then 
given sublingually and the patient assumed 
upright posture. Pulse rate was counted for 
6 min and the highest rate during any 30-sec 
interval was used for comparison with the 
initial recumbent rate. 
Isoproterenol infusion. Isoproterenol was 
administered into the superior vena cava uti-
lizing a constant infusion pump while moni-
toring heart rate electrocardiographically. A 
solution of 1.0 ILg/ml of isoproterenol in saline 
(0.8%) was used. During the period of placebo 
treatment three rates of infusion were tested, 
1.0, 2.0, and 3.0 J.tg/min, each for 3 min. 
Heart rate at the end of each 3 min period was 
compared to the heart rate before infusion. 
Passive tilt. Heart rate was measured from a 
continuously recorded electrocardiogram. Basal 
readings were obtained during horizontal rest 
for at least 15 min on a tilt table with a saddle. 
The table was then tilted for 10 min to a 45 0 
head-up position. Heart rate at the end of this 
period was compared to the basal rate . 
Standing. Pulse rate was measured at the 
wrist by the same two nurses in the clinic 
throughout the study. Visits were always in 
the morning. Basal heart rate was determined 
after 15 min of recumbent rest . Pulse rate was 
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Fig. 2. TNG test results (± SEM) before and during 
propranolol therapy. Patients treated with 160 mg/ 
day throughout (open circles) compared to those 
increased to 320 mg/day during weeks 3 and 4 
(closed circles). Clear bars refer to low-dose pro-
pranolol group and cross-hatched bars, the high-dose 
group. 
measured again after 2 min of quiet standing. 
Heart rate after standing was compared to the 
basal rate. 
Plasma propranolol determinations. Plas-
ma propranolol concentration was measured 
by fluorometry . * 15 Blood samples were drawn 
approximately 90 min after the last dose of 
propranolol following 2 and 4 wk of oral ther-
apy . The plasma was separated by centrifuga-
tion and chilled at 4 0 C before being sent for 
analysis . 
Experimental design. All patients were 
given placebo, I tablet 4 times daily, for 4 wk. 
After this period the effects of standing and of 
nitroglycerin tests were determined in the 
clinic . The tilt test and isoproterenol infusions 
were then carried out in the Clinical Physiology 
Laboratory. t 
Patients then took propranolol orally in a 
dose of 40 mg, 4 times daily . After 2 wk they 
returned to the clinic where the effects of 
standing and nitroglycerin plus standing were 
determined again. Samples for plasma pro-
pranolol concentration measurement were also 
obtained . Those patients who demonstrated a 
satisfactory therapeutic response (a reduction 
• Courtesy of Ayerst Laboratories , Montreal , Dr. Henry LeMien , 
Jr. 
t Dr. Stevo Julius, Director. 
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Table III. Heart rate increments in beats Imin (± SEM) during stimulating maneuvers in high- and 
low-dose groups 
Placebo Propranolol (2 wk) 
Nitro-
I I I 
Nitro-
I I 
PPL 
Group glycerin Isoproterenol Tilt Standing glycerin Standing (ng Iml) 
Low dose 41.3 42.1 8.3 9.8 20.0* 5.6 63.4 
(160 mg ( 4.3) ( 5.5) (4.4) (4.8) ( 4.0) (2.2) ( 12.1) 
propranolol/day) 
High dose 32.6 39.1 8.6 8.5 22.2 6.8 50.1 
(160-320 mg ( 3.0) ( 4.8) (1.5) (3.0) ( 5.3) (1.5) (16.2) 
propranolol/day) 
PPL: plasma propranolol concentration (nanograms/mI). 
Heart rate response in patients treated with propranolol. 160 mg/day throughout, and those observed in patients whose incomplete blood pressure 
change after 2 wk required an increase in dosage to 320 mg/day. 
Statistical comparisons between high- and low-dose groups (Student's t test) were all p > 0.05. 
Statistical comparisons within groups, compared to the immediately preceding values (paired t test), *p < 0.05; tp < 0.01. 
of recumbent diastolic blood pressure in the 
clinic of at least 15 mm Hg or a recumbent 
clinic reading of less than 150/90) were ad-
vised to continue to take propranolol, 40 mg, 
4 times daily, while in those with a poorer 
response the dose was increased to 80 mg 4 
times daily. 
Dosage was kept at 160 mg daily in 8 pa-
tients and increased to 320 mg daily in 7 pa-
tients, and all patients returned for final obser-
vations after 2 wk at these dosage levels. 
Tests performed at this visit included the effects 
of standing and of nitroglycerin plus standing 
in the clinic and the tilt test and isoproterenol 
infusion in the Clinical Physiology Laboratory. 
Finally, blood for plasma propranolol concen-
tration was also obtained. 
Statistical methods. Student's t test, the t 
test for paired observations and correlation 
coefficients were calculated using the Midas 
(Constat) Computer Program of the Statistical 
Research Laboratory at the University of 
Michigan. 
Results 
The effects on heart rate of the maneuvers 
used were as expected most pronounced dur-
ing placebo treatment (Table II); the nitro-
glycerin and standing test (TNG test) caused 
an increase in heart rate of 37 beats/min. The 
various infusion rates of isoproterenol in-
creased heart rate between 12 and 41 beats I 
min (Fig_ 1). Correlations between TNG test 
and isoproterenol infusion were significant for 
infusion rates of 2.0 and 3.0 JLg/min- Since 
the stronger correlation was after 3.0 JLg/min 
(r = 0.633, p < 0.005), only this infusion 
rate was used after propranolol therapy, and 
heart rate response to only this dose are sum-
marized in Table II. Heart rate increments 
during both passive tilt and quiet standing 
were similar, and considerably less than those 
observed after isoproterenol or TNG. 
TNG test responses were halved during 
propranolol treatment, and most of this effect 
was established after 2 wk of therapy, whereas 
the isoproterenol response (after 4 wk) was 
reduced to 15% of control values by proprano-
lol. On a percentage basis, modification of 
the responses to tilt and standing was quan-
titatively similar to that noted with the TNG 
test. 
Analysis of data obtained from patients 
divided into subsets based on treatment protocol 
("low" dose and "high" dose) revealed no 
statistically significant differences between the 
two groups (Table III) but within-group com-
parisons were significant. The blunting of TNG 
test response after 2 wk of propranolol 
achieved statistical significance in the low-dose 
but not in the high-dose group. The blockade 
of isoproterenol tachycardia was significant 
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Propranolol (4 wk) 
Nitro- PPL 
glycerin Isoproterenol (nglml) 
IS.S 6.2t 4.0 7.6 63.3 
( I.S) (1.4) (2.0) (3.1 ) (14.S) 
IS.4* 4.St I.S* I "* • .J 144.0 
( 4.2) (1.6) (0.5) ( 1.5) (72.3) 
in both groups, while the impairment of re-
sponses to both tilt and standing was signifi-
cant only in the high-dose subset during the 
320 mg/day dosage. The small decrement in 
TNG response noted between weeks 2 and 4 
of propranolol therapy (Fig. 2) was significant 
only in the group of patients switched from 
160 to 320 mg/day. There was a correlation 
between the heart rate responses to TNG and 
isoproterenol after 4 wk of propranolol ther-
apy (r = 0.65, P < 0.03). 
Discussion 
These data reveal that cardiac acceleration 
after administration of nitroglycerin and as-
sumption of the erect posture (TNG test) is di-
minished during propranolol therapy. The find-
ings are consistent with those of Fitzgerald with 
nitroglycerin6 and with standing. 5 We were 
also able to demonstrate a significant correla-
tion between cardiac response to isoproterenol 
infusion and TNG test results both in the control 
state and during propranolol therapy. Our data 
therefore provide support for Fitzgerald's 
suggestion that TNG testing is a means for 
assessing the degree of adrenergic beta recep-
tor blockade. However, we did not observe 
obliteration of the TNG response during treat-
ment with propranolol at a dose of 320 mg/day 
even though plasma propranolol concentrations 
were at full beta blocking levels. 2 We found 
almost maximal inhibition of tachycardia at the 
160 mg/day dosage (Fig. 2). The slope of the 
dose-response curve suggests that complete 
blockade of this response would not have been 
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attained even at much higher dosage. These 
latter observations cast doubt on the concept 
that the heart rate response to nitroglycerin 
is mediated purely by the sympathetic nervous 
system6 and are supported by the recent report 
of Ekue, Shanks, and Walsh. 3 They conflict 
with the results of a study of reflex heart rate 
control in normal men,12 which indicated that 
the change of heart rate due to hypotension 
induced by amyl nitrite is mediated largely 
by the parasympathetic nervous system. It 
appears more likely that the tachycardia in-
duced by nitroglycerin in our hypertensive 
subjects is a result of both sympathetic stim-
ulation and vagal withdrawal. This picture 
is compatible with the traditional view that 
heart rate responses are the result of a balance 
between sympathetic and parasympathetic sys-
tems 14 and is in agreement with recent work in 
dogs on the mechanism of baroreceptor-induced 
changes in heart rate. 16 
It is obvious, therefore, that the TNG test is 
of limited value in the assessment of beta 
adrenergic blockade, as responses to it are de-
termined in some part by the parasympathetic 
nervous system. Only if the vagal component 
could be regarded as constant could changes 
in heart rate due to nitroglycerin be ascribed to 
changes in the degree of beta blockade. This 
test has been helpful in our study, however, in 
the assessment of the completeness of blockade 
in a group of subjects and thereby helped to 
provide information on the maximum dose of 
propranolol required when it is used in the treat-
ment of hypertension. 
The capability of propranolol to lower blood 
pressure in hypertensive patients is almost 
certainly related to its beta adrenergic receptor 
blocking activity. 11 There is some suggestion, 
however, that beta-blocking drugs in higher 
dose or after a longer period of time may have 
additional antihypertensive properties. 13 In a 
separate paper, based on additional data ob-
tained from the same subjects in the present 
study,8 we reported that in most patients the 
reduction in blood pressure observed at the dose 
of 320 mg of propranolol per day was the same 
as that seen at 160 mg/day. Coupled with the 
current finding that, based on the TNG test, 
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Fig. 3. Correlation between TNG-induced tachycar-
dia and heart rate response to isoproterenol infusion 
after 4 wk of propranolol administration, Subjects 
from both high- and low-dose groups are included, 
nearly complete cardiac beta blockade is pres-
ent at the 160 mg/day dosage, this suggests 
that at least in the mild hypertensive propran-
olol lowers blood pressure primarily because 
of its action as a beta blocker. It also suggests 
that in treating such patients there is no need 
to administer more than a beta-blocking dose 
of propranolol. 
Our data, from the TNG test and responses 
to quiet standing and tilt indicate that a slightly 
greater degree of beta blockade can be obtained 
with propranolol in a dose of 320 mg/day than 
with 160 mg / day. It is therefore justifiable to 
consider prescribing 320 mg/ day to selected 
patients with hypertension who respond in-
adequately to the lower dosage. 
A final point of interest is the fact that the 
TNG test response was inhibited significantly 
during the first treatment period only in the 
group of patients who required the lesser dose 
of medication for blood pressure control. The 
data suggest that the main reason for this dif-
ference is that those patients with the most 
substantial blood pressure responses to 160 mg 
propranolol per day had greater heart rate 
increments during the control TNG test. This 
finding hints at the often studied,!' 8 but rarely 
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substantiated4 relationship between the ability 
of beta blockers to lower blood pressure and 
the activity of the sympathetic nervous system 
in hypertensive patients . 
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